Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Revance Therapeutics beat estimated earnings by 8.82%, reporting an EPS of $-0.93 versus an estimate of $-1.02.
Revenue was up $14.82 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.05 which was followed by a 5.03% increase in the share price the next day.
Here's a look at Revance Therapeutics's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -1.15 | -1.05 | -1.09 | -1.24 |
| EPS Actual | -1.10 | -1.07 | -1.08 | -1.24 |
| Revenue Estimate | 20.29M | 15.48M | 10.98M | 8.78M |
| Revenue Actual | 19.75M | 18.80M | 13.30M | 11.13M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
